sitagliptin and metformin
Drugsitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
Other names: DPP
NCT Number: NCT05480007
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A major unanswered question concerns the potential ability of DPP-4I to improve intrahepatic lipid (IHL) content in nonalcoholic fatty liver disease (NAFLD) patients. The aim of this study was to evaluate the effects of sitagliptin on IHL in NAFLD patients.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
A prospective, 24-week, single-center, open-label, comparative study enrolled 68 Chinese NAFLD patients with T2DM. Subjects were randomly divided into 4 groups: control group who did not take medicine (14 patients); sitagliptin group who received sitagliptin treatment (100mg per day) (17 patients); metformin group who received metformin (500mg three times per day) (17 patients); and sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients). IHL, physical examination (waist circumstances, WC; body mass index, BMI), glucose-lipid metabolism (fasting plasma glucose, FPG; hemoglobin A1c, Hb1A1c; triglycerides; cholesterol; alanine aminotransferase, ALT; aspartate aminotransferase, AST) were measured at baseline and at 24 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
Other names: DPP
sitagliptin treatment (100mg per day)
metformin group who received metformin (500mg three times per day)
Time frame: 24weeks
hepatic steatosis
Shanghai 10th People's Hospital
Other
Effect of DPP-4I and Related Treatment on Non-alcoholic Fatty Liver Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04248335
Body Weight, Deglutition Disorders
Kansas City, Missouri, United States
View Trial DetailsNCT05370053
Digestive System Diseases, Fatty Liver
Kansas City, Kansas, United States
View Trial DetailsNCT06697977
Body Weight, Diabetes
Amman, Jordan
View Trial DetailsNCT06410924
Digestive System Diseases, Fatty Liver
Maitland, Florida, United States
View Trial Details